Valneva Stock Rises 5.83% After a 35% Drop Over Three Months

Technical Rebound Amidst Ongoing Challenges

Valneva's stock price rebounded this morning after hitting its support level at €2.58 the previous day, a level that also corresponds to the recent low of the stock. This bullish movement occurs in a severely degraded technical context: the RSI, a momentum indicator, is at 24, signaling a pronounced oversold zone and suggesting that the selling pressure over the last few weeks might have been excessive. Moreover, the price is significantly below its 50-day (€4.11) and 200-day (€3.88) moving averages, confirming that the underlying trend remains downward despite today's rebound.
In the Bollinger Bands, the stock is at the lower 24% range, much closer to the lower boundary (€1.77) than the upper boundary (€5.67). The width of these bands reflects the high volatility characterizing the stock in recent weeks, with an indicator at 23.18 over a month. In comparison, other healthcare sector stocks show more modest changes this morning: Sanofi is up by 1.09% and UCB by 0.99%.

Key Dates Ahead for Valneva Shareholders

The next major event for Valneva shareholders is scheduled for May 7, when the company will release its first-quarter 2026 results. This announcement will be closely monitored as the stock has lost more than a third of its value in three months and is down 2.47% over the year. The general assembly will take place on June 1, followed by the semi-annual results expected on August 13.
The beta of the stock, at 0.33, indicates a relatively low sensitivity to general market movements. Today's rise, more pronounced than that of the overall Parisian market, seems more linked to the specific configuration of the stock than to the overall improvement of European indices. The most significant technical resistance is at €5.08, nearly double the current price, illustrating the extent of the recovery needed for the stock to return to its levels at the beginning of the year.